- Report
- August 2022
Global
From €945EUR$990USD£792GBP
- Report
- July 2023
- 218 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- September 2020
- 65 Pages
Global
€1258EUR$1,318USD£1,054GBP
- Report
- January 2024
- 85 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2022
- 182 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Psoriatic Arthritis Drug is a type of drug used to treat psoriatic arthritis, a type of immune disorder. It is a chronic, inflammatory condition that affects the joints and skin. Psoriatic Arthritis Drug works by targeting the underlying cause of the disease, which is an overactive immune system. It helps to reduce inflammation and pain, and can also slow down the progression of the disease. Commonly used Psoriatic Arthritis Drugs include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).
The Psoriatic Arthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of psoriatic arthritis, as well as the development of new and more effective treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for them increases.
Some of the major companies in the Psoriatic Arthritis Drug market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and Roche. Show Less Read more